Cargando…

Identification of DPP4/CTNNB1/MET as a Theranostic Signature of Thyroid Cancer and Evaluation of the Therapeutic Potential of Sitagliptin

SIMPLE SUMMARY: In recent years, the incidence of thyroid cancer has been increasing globally, with papillary thyroid cancer (PTCa) being the most prevalent pathological type. Although PTCa has been regarded to be slow growing and has a good prognosis, in some cases, PTCa can be aggressive and progr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Sheng-Yao, Wu, Alexander T. H., Batiha, Gaber El-Saber, Ho, Ching-Liang, Lee, Jih-Chin, Lukman, Halimat Yusuf, Alorabi, Mohammed, AlRasheedi, Abdullah N., Chen, Jia-Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869712/ https://www.ncbi.nlm.nih.gov/pubmed/35205190 http://dx.doi.org/10.3390/biology11020324

Ejemplares similares

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahrén, Bo
Publicado: (2010)

Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy?
por: Alomair, Basil Mohammed, et al.
Publicado: (2022)

A Systematic Review of Phytochemistry, Nutritional Composition, and Pharmacologic Application of Species of the Genus Viola in Noncommunicable Diseases (NCDs)
por: Batiha, Gaber El-Saber, et al.
Publicado: (2023)

Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes
por: Koyani, Chintan N., et al.
Publicado: (2018)

Sitagliptin, a DPP-4 Inhibitor, Acutely Inhibits Intestinal Lipoprotein Particle Secretion in Healthy Humans
por: Xiao, Changting, et al.
Publicado: (2014)

Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells
por: Yoon, Hyunyee, et al.
Publicado: (2021)

Cytotoxicity and anti-HIV activities of extracts of the twigs of Croton dichogamus Pax
por: Terefe, Ermias Mergia, et al.
Publicado: (2022)

DPP4 Inhibitor Sitagliptin Enhances Lymphocyte Recruitment and Prolongs Survival in a Syngeneic Ovarian Cancer Mouse Model
por: Wilson, Amy L., et al.
Publicado: (2021)

Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2022)

Zingiber officinale and Vernonia amygdalina Infusions Improve Redox Status in Rat Brain
por: Rotimi, Damilare Emmanuel, et al.
Publicado: (2022)

CTNNB1 in neurodevelopmental disorders
por: Zhuang, Wenting, et al.
Publicado: (2023)

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice
por: Berger, Joel P., et al.
Publicado: (2017)

The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms
por: Zeng, Yanmei, et al.
Publicado: (2014)

A Physiologically‐Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP‐1 and GIP and the DPP4 Inhibitor Sitagliptin
por: Balazki, Pavel, et al.
Publicado: (2020)

Retraction: MiR-206 reduced the malignancy of hepatocellular carcinoma cells in vitro by inhibiting MET and CTNNB1 gene expressions
por: Fisher, Laura
Publicado: (2021)

Novel Potentials of the DPP-4 Inhibitor Sitagliptin against Ischemia-Reperfusion (I/R) Injury in Rat Ex-Vivo Heart Model
por: Al-awar, Amin, et al.
Publicado: (2018)

Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus
por: Katsuno, Tomoyuki, et al.
Publicado: (2016)

The Role of CTNNB1 in Endometrial Cancer
por: Ledinek, Živa, et al.
Publicado: (2022)

Retracted Article: MiR-206 reduced the malignancy of hepatocellular carcinoma cells in vitro by inhibiting MET and CTNNB1 gene expressions
por: He, Qiang, et al.
Publicado: (2019)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

CTNNB1 Mutation in Aldosterone Producing Adenoma
por: Wang, Jian-Jhong, et al.
Publicado: (2017)

CTNNB1 mutations are clonal in adamantinomatous craniopharyngioma
por: Apps, J. R., et al.
Publicado: (2020)

Recurrent CTNNB1 mutations in craniofacial osteomas
por: Baumhoer, Daniel, et al.
Publicado: (2021)

DPP-4 inhibitor sitagliptin prevents inflammation and oxidative stress of heart and kidney in two kidney and one clip (2K1C) rats
por: Alam, Md. Ashraful, et al.
Publicado: (2015)

Characteristics of Elderly Patients Initiating Sitagliptin or Non-DPP-4-Inhibitor Oral Antihyperglycemic Agents: Analysis of a Cross-Sectional US Claims Database
por: Wang, Tongtong, et al.
Publicado: (2018)

Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy
por: Furuhashi, Masato, et al.
Publicado: (2022)

Cholinergic dysfunction in COVID-19: frantic search and hoping for the best
por: Nadwa, Eman Hassan, et al.
Publicado: (2022)

The prevalence of burnout among interns in Riyadh, Saudi Arabia, and its relation to engaging in unethical behaviors
por: Ali, Shatha, et al.
Publicado: (2021)

Traditional herbs against COVID-19: back to old weapons to combat the new pandemic
por: Al-kuraishy, Hayder M., et al.
Publicado: (2022)

Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor omarigliptin or the once‐daily DPP‐4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
por: Goldenberg, Ronald, et al.
Publicado: (2017)

PERsistent Sitagliptin treatment & Outcomes (PERS&O 2.0) study, long-term results: a real-world observation on DPP4-inhibitor effectiveness
por: Bossi, Antonio Carlo, et al.
Publicado: (2020)

Targeting DPP4-RBD interactions by sitagliptin and linagliptin delivers a potential host-directed therapy against pan-SARS-CoV-2 infections
por: Mani, Shailendra, et al.
Publicado: (2023)

AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug Sitagliptin for the Management of Hepatocellular Carcinoma
por: Abd El-Fattah, Eslam E., et al.
Publicado: (2022)

Activating mutations in CTNNB1 in aldosterone producing adenomas
por: Åkerström, Tobias, et al.
Publicado: (2016)

Transcriptomic Characterization of Hepatocellular Carcinoma with CTNNB1 Mutation
por: Ding, Xiao, et al.
Publicado: (2014)

Citicoline and COVID-19: vis-à-vis conjectured
por: Al-kuraishy, Hayder M., et al.
Publicado: (2022)

Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure
por: Al‐kuraishy, Hayder M., et al.
Publicado: (2022)

Sitagliptin-induced hemolysis
por: Bekur, Ragini, et al.
Publicado: (2010)

Sitagliptin-Associated Angioedema
por: Gosmanov, Aidar R., et al.
Publicado: (2012)

Dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin alleviates liver inflammation of diabetic mice by acting as a ROS scavenger and inhibiting the NFκB pathway
por: Wang, Xin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7iivbcr0agske1hgh56klah1k0